Tagged with Hong Kong

Hong Kong In March 2024, the Advanced Therapy Product Good Manufacturing Practice Centre (ATP GMP Centre) at the Chinese University of Hong Kong’s (CUHK) Institute of Biotechnology (HKIB) became the first university-led centre within the special administrative region to receive certification for cell and gene therapy manufacturing and a license as an…

Hong Kong With global momentum building around CRISPR-based therapeutics, GenEditBio stands at the frontier of in vivo genome editing, developing next-generation delivery platforms designed for both precision and safety. In this conversation, Dr Zongli Zheng, Co-founder and Chair, shares how his scientific path from Boston to Hong Kong, shaped by pioneering work…

Hong Kong Few biotech companies emerge with both scientific depth and a clear sense of direction. Innorna, founded by Dr Linxian Li after years spent refining RNA delivery systems in academic settings, is one of them. What began as a technical platform matured through a pandemic-era proof of concept and now moves…

Hong Kong At the Centre for Oncology and Immunology, a flagship of Hong Kong’s Health@InnoHK initiative, science converges across disciplines and continents. Under the leadership of Professor Tak Wah Mak, the Centre is advancing a new understanding of how immune responses are shaped, not only by tumours, but by the nervous system…

Hong Kong With Asia-Pacific poised to become a global force in cell and gene therapy, Xellera Therapeutics is positioning itself at the heart of this transformation. Led by CEO Camie Chan, the Hong Kong-based company is bridging critical infrastructure gaps by offering GMP-certified manufacturing, regulatory compliance aligned with global standards, and a…

Hong Kong Professor Guangjin Pan, Managing Director of the Centre for Regenerative Medicine and Health (CRMH), discusses how the center’s focuses on translating cutting-edge science into clinical and commercial success – driving Hong Kong’s ambition to become a global biotech hub. As Part of the Hong Kong Institute of Science & Innovation…

Hong Kong A long-standing figure in Hong Kong’s haematology landscape, Professor Kenny Lei has played a pivotal role in advancing lymphoma care and cellular therapies over the past three decades. His contributions span the early adoption of autologous peripheral blood stem cell transplantation and active involvement in establishing the city’s first hospital-based…

Hong Kong In recent years, the Hong Kong Institute of Biotechnology (HKIB) has entered a new phase, shifting from the groundwork of facility-building to the clinical delivery of locally manufactured CAR-T therapies. Managing Director Gina Jiang reflects on this transition and shares how early operational lessons are in forming a wider platform…

Hong Kong In our field, success is not defined by short-term remission alone, but by long-term disease eradication. Our goal is always a cure, not prolonged management. After decades spent advancing paediatric oncology in Hong Kong, Professor Li Chi Kong has increased his focus toward the frontier of cell and gene therapies, spearheading…

Hong Kong For anyone seeking a place where world-class science and a balanced lifestyle can coexist, Hong Kong offers a uniquely compelling proposition. As China’s pharmaceutical landscape expands into innovative biologics, SPH Biotherapeutics (HK) – an R&D affiliate of Shanghai Pharma – is advancing a dual-targeting CAR-T platform with early clinical results…

Merck Over the course of its 350-year history, Merck KGaA has expanded from its base in Darmstadt, Germany to establish a strong presence in various markets across the globe. Last year, PharmaBoardroom spoke with Merck affiliate leaders in multiple geographies, uncovering their concerns and priorities as the firm pushed to recover…

Hong Kong Hong Kong has grand plans to become one of Asia’s leading clinical trial hubs. Important regulatory upgrades and increased integration with mainland China via the Greater Bay Area initiative – including a new dedicated GBA Clinical Trial Institute at the Hong Kong/mainland border – mean that this is not just…